Cipla Limited (NSE:CIPLA)
India · Delayed Price · Currency is INR 1,434.50
-13.80 (-0.95%)
Jan 14, 2026, 3:30 PM IST
Cipla Revenue
Cipla had revenue of 74.47B INR in the quarter ending September 30, 2025, with 6.98% growth. This brings the company's revenue in the last twelve months to 279.66B, up 6.48% year-over-year. In the fiscal year ending March 31, 2025, Cipla had annual revenue of 272.67B with 6.78% growth.
Revenue (ttm)
279.66B
Revenue Growth
+6.48%
P/S Ratio
4.18
Revenue / Employee
9.23M
Employees
30,313
Market Cap
1.17T
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2025 | 272.67B | 17.31B | 6.78% |
| Mar 31, 2024 | 255.37B | 29.77B | 13.20% |
| Mar 31, 2023 | 225.59B | 8.51B | 3.92% |
| Mar 31, 2022 | 217.08B | 25.87B | 13.53% |
| Mar 31, 2021 | 191.21B | 20.40B | 11.94% |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Sun Pharmaceutical Industries | 549.64B |
| Aurobindo Pharma | 325.14B |
| Zydus Lifesciences | 244.94B |
| Apollo Hospitals Enterprise | 232.65B |
| Biocon | 164.76B |
| Glenmark Pharmaceuticals | 159.97B |
| Alkem Laboratories | 138.90B |
| Mankind Pharma | 135.46B |
Cipla News
- 6 days ago - Top stocks to watch today, January 8: Infosys, Tata Steel, HUDCO, Gland Pharma, Angel One, Cipla and more - Business Upturn
- 7 days ago - Why are Cipla shares down over 3% in trade today? Details - Business Upturn
- 13 days ago - Nifty 50 top losers today, January 1: ITC, Dr. Reddy’s, Bajaj Finance, Tata Consumer Products, ONGC, Cipla and more - Business Upturn
- 14 days ago - Dr Reddy, Cipla, Sun Pharma and other stocks in focus today as Govt bans high-dose Nimesulide formulations - Business Upturn
- 15 days ago - Breaking Barriers in Diabetes Care: Cipla Launches #InhaleTheChange Campaign - Business Upturn
- 19 days ago - Nifty 50 top gainers today, December 26: Titan Company, Nestle India, Hindalco Industries, Cipla and more - Business Upturn
- 26 days ago - Pfizer signs exclusive 5-year supply and marketing pact with Cipla for four key brands - Business Upturn
- 4 weeks ago - Cipla launches Yurpeak, a weekly injection for obesity and type 2 diabetes - Business Upturn